Skip to main content

Table 2 Descriptive and univariate survival analysis according to treatment feature

From: Prognostic factors of BRAF V600E colorectal cancer with liver metastases: a retrospective multicentric study

Treatment characteristic Median OS (months) P value
CRLM surgery
 Yes 34 P < 0.0001
 No 10.6
Upfront CRLM surgery
 Yes 33 P = 0.3402
 No 34
Postoperative OS 28 NC
Exclusive chemotherapy 11.5 NC
FOLFIRINOX +/− bevacizumab 16.6 NC
  1. CRLM Colorectal liver metastases, OS Overall survival, NC Not concerned